Polyreactive antibodies in adaptive immune responses to viruses

Cellular and Molecular Life Sciences

Volumn 69, Issue 9, 2012, Pages 1435-1445

  Mouquet, Hugo ^a   Nussenzweig, Michel C ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Antibodies; B cells; HIV; Polyreactivity; Tolerance; Viruses

Indexed keywords

ANTIBODY; B LYMPHOCYTE RECEPTOR; CD40 ANTIGEN; CD40 LIGAND; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; POLYREACTIVE ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; AUTOIMMUNITY; B LYMPHOCYTE; CHICKENPOX; CROSS REACTION; GERMINAL CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; LYMPHOCYTE CLONE; LYMPHOCYTIC CHORIOMENINGITIS; MEASLES; MUMPS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION; VACCINIA; VESICULAR STOMATITIS; VIRUS IMMUNITY; ANTIBODY AFFINITY; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; VIRUS; VIRUS INFECTION;

ADAPTIVE IMMUNITY; AIDS VACCINES; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; HIV ANTIBODIES; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, HUMORAL; IMMUNITY, INNATE; VIRUS DISEASES; VIRUSES;

EID: 84862314634     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0872-6     Document Type: Review

References (154)

1. Landsteiner K, Pauling L, Landsteiner EK (1945) The specificity of serological reactions. Rev. edn. Harvard University Press, Cambridge
2. Casali P, Notkins AL (1989) Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. Annu Rev Immunol 7:513-535. doi:10.1146/annurev.iy.07. 040189.002501 (Pubitemid 19138022)
3. Bouvet JP, Dighiero G (1998) From natural polyreactive auto-antibodies to a la carte monoreactive antibodies to infectious agents: is it a small world after all? Infect Immun 66(1):1-4
4. Notkins AL (2004) Polyreactivity of antibody molecules. Trends Immunol 25(4):174-179. doi:10.1016/j.it.2004.02.004 (Pubitemid 38368164)
5. Zhou ZH, Tzioufas AG, Notkins AL (2007) Properties and function ofpolyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun 29(4):219-228. doi:10.1016/j.jaut.2007.07.015 (Pubitemid 47633150)
6. Eisen HN, Chakraborty AK (2010) Evolving concepts of spec-ificity in immune reactions. Proc Natl Acad Sci USA 107(52): 22373-22380. doi:10.1073/pnas.1012051108
7. Guilbert B, Dighiero G, Avrameas S (1982) Naturally occurring antibodies against nine common antigens in human sera. I. Detection, isolation and characterization. J Immunol 128(6): 2779-2787 (Pubitemid 12124516)
8. Dighiero G, Guilbert B, Avrameas S (1982) Naturally occurring antibodies against nine common antigens in humans sera. II. High incidence of monoclonal Ig exhibiting antibody activity against actin and tubulin and sharing antibody specificities with natural antibodies. J Immunol 128(6):2788-2792 (Pubitemid 12124517)
9. Dighiero G, Lymberi P, Mazie JC, Rouyre S, Butler-Browne GS, Whalen RG, Avrameas S (1983) Murine hybridomas secreting natural monoclonal antibodies reacting with self anti-gens. J Immunol 131(5):2267-2272 (Pubitemid 14227421)
10. Dighiero G, Guilbert B, Fermand JP, Lymberi P, Danon F, Avrameas S (1983) Thirty-six human monoclonal immuno-globulins with antibody activity against cytoskeleton proteins, thyroglobulin, and native DNA: immunologic studies and clin-ical correlations. Blood 62(2):264-270 (Pubitemid 13036071)
11. Eisen HN, Michaelides MC, Underdown BJ, Schulenburg EP, Simms ES (1970) Experimental approaches to homogenous antibody populations. Myeloma proteins with antihapten anti-body activity. Fed Proc 29(1):78-84
12. Michaelides MC, Eisen HN (1974) The strange cross-reaction of menadione (vitamin K3) and 2, 4-dinitrophenyl ligands with a myeloma protein and some conventional antibodies. J Exp Med 140(3):687-702
13. James LC, Tawfik DS (2003) The specificity of cross-reactivity: promiscuous antibody binding involves specific hydrogen bonds rather than nonspecific hydrophobic stickiness. Protein Sci 12(10):2183-2193. doi:10.1110/ps.03172703 (Pubitemid 37163352)
14. Keitel T, Kramer A, Wessner H, Scholz C, Schneider-Mergener J, Hohne W (1997) Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity. Cell 91(6):811-820. pii:S0092-8674(00) 80469-9 (Pubitemid 28007737)
15. Kramer A, Keitel T, Winkler K, Stocklein W, Hohne W, Schneider-Mergener J (1997) Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody. Cell 91(6):799-809. pii:S0092-8674(00)80468-7 (Pubitemid 28007736)
16. Shlomchik MJ, Aucoin AH, Pisetsky DS, Weigert MG (1987) Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. Proc Natl Acad Sci USA 84(24): 9150-9154
17. Marchalonis JJ, Adelman MK, Robey IF, Schluter SF, Edmundson AB (2001) Exquisite specificity and peptide epitope recognition promiscuity, properties shared by antibodies from sharks to humans. JMol Recognit 14(2):110-121. doi:10.1002/jmr.527 (Pubitemid 32418039)
18. Casali P, Burastero SE, Nakamura M, Inghirami G, Notkins AL (1987) Human lymphocytes making rheumatoid factor and antibody to ss DNA belong to Leu-1+ B-cell subset. Science 236(4797):77-81 (Pubitemid 17056816)
19. Nakamura M, Burastero SE, Ueki Y, Larrick JW, Notkins AL, Casali P (1988) Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells pro-ducing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. J Immunol 141(12):4165-4172 (Pubitemid 19018201)
20. Nakamura M, Burastero SE, Notkins AL, Casal P (1988) Human monoclonal rheumatoid factor-like antibodies from CD5 (Leu-1) + B cells are polyreactive. J Immunol 140(12):4180-4186
21. Ichiyoshi Y, Casali P (1994) Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chi-meric human immunoglobulin heavy and light chain V segments. J Exp Med 180(3):885-895 (Pubitemid 24256601)
22. Aguilera I, Melero J, Nunez-Roldan A, Sanchez B (2001) Molecular structure of eight human autoreactive monoclonal antibodies. Immunology 102(3):273-280. pii:imm1159
23. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC (2003) Predominant autoantibody production by earlyhuman B cellprecursors. Science301(5638):1374-1377. doi: 10.1126/science. 1086907 (Pubitemid 37075812)
24. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC (1997) Structural insights into the evolution of an antibody combining site. Science 276(5319):1665-1669 (Pubitemid 27421966)
25. Manivel V, Sahoo NC, Salunke DM, Rao KV (2000) Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity 13(5):611-620. pii:S1074-7613(00)00061-3
26. Jimenez R, Salazar G, Baldridge KK, Romesberg FE (2003) Flexibility and molecular recognition in the immune system. Proc Natl Acad Sci USA 100(1):92-97. doi:10.1073/pnas.262411 399 (Pubitemid 36078035)
27. Krishnan L, Lomash S, Raj BP, Kaur KJ, Salunke DM (2007) Paratope plasticity in diverse modes facilitates molecular mim-icry in antibody response. J Immunol 178(12):7923-7931. pii:178/12/7923
28. Krishnan L, Sahni G, Kaur KJ, Salunke DM (2008) Role of antibody paratope conformational flexibility in the manifestation of molecular mimicry. Biophys J 94(4):1367-1376. doi: 10.1529/biophysj.107.108654
29. Foote J, Milstein C (1994) Conformational isomerism and the diversity of antibodies. Proc Natl Acad Sci USA 91(22): 10370-10374 (Pubitemid 24328998)
30. Ma B, Shatsky M, Wolfson HJ, Nussinov R (2002) Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations. Protein Sci 11(2):184-197. doi:10.1110/ps.21302 (Pubitemid 34075781)
31. Bhat TN, Bentley GA, Fischmann TO, Boulot G, Poljak RJ (1990) Small rearrangements in structures of Fv and Fab fragments of antibody D1.3onantigenbinding.Nature347(6292):483-485. doi: 10.1038/347483a0 (Pubitemid 20329990)
32. Sethi DK, Agarwal A, Manivel V, Rao KV, Salunke DM (2006) Differential epitope positioning within the germline antibody paratope enhances promiscuity in the primary immune response. Immunity 24(4):429-438. doi:10.1016/j.immuni. 2006.02. 010
33. Mariuzza RA (2006) Multiple paths to multispecificity. Immu-nity 24(4):359-361. doi:10.1016/j.immuni.2006.03.009
34. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM (2005) Cardiolipin polyspecific auto-reactivity in two broadly neutralizing HIV-1 antibodies. Science 308(5730):1906-1908. doi:10.1126/science.1111781 (Pubitemid 40941873)
35. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323(5921):1610-1614. doi: 10.1126/science.1165480
36. Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302(5909):575-581
37. Weigert MG, Cesari IM, Yonkovich SJ, Cohn M (1970) Vari-ability in the lambda light chain sequences of mouse antibody. Nature 228(5276):1045-1047
38. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG (2005) Cellular and genetic mechanisms of self tolerance and autoimmu-nity. Nature 435(7042):590-597. doi:10.1038/nature03724 (Pubitemid 40825498)
39. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, Wardemann H (2006) A checkpoint for autoreactivity in human Ig M+ memory B cell development. J Exp Med 203(2):393-400. doi:10.1084/jem.20052033 (Pubitemid 43290848)
40. Yurasov S, Tiller T, Tsuiji M, Velinzon K, Pascual V, Warde-mann H, Nussenzweig MC (2006) Persistent expression of autoantibodies in SLE patients in remission. J Exp Med 203(10):2255-2261. doi:10.1084/jem.20061446 (Pubitemid 44498360)
41. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201(5):703-711. doi: 10.1084/jem.20042251 (Pubitemid 40395116)
42. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E (2005) Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 201(10):1659-1667. doi:10.1084/jem.20042321 (Pubitemid 40721009)
43. Menard L, Samuels J, Ng YS, Meffre E (2011) Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum 63(5):1237-1245. doi: 10.1002/art.30164
44. Menard L, Saadoun D, Isnardi I, Ng YS, Meyers G, Massad C, Price C, Abraham C, Motaghedi R, Buckner JH, Gregersen PK, Meffre E (2011) The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest. doi:10.1172/JCI45790
45. Ng YS, Wardemann H, Chelnis J, Cunningham-Rundles C, Meffre E (2004) Bruton's tyrosine kinase is essential for human B cell tolerance. J Exp Med 200(7):927-934. doi:10.1084/jem. 20040920 (Pubitemid 38252049)
46. Isnardi I, Ng YS, Srdanovic I, Motaghedi R, Rudchenko S, von Bernuth H, Zhang SY, Puel A, Jouanguy E, Picard C, Garty BZ, Camcioglu Y, Doffinger R, Kumararatne D, Davies G, Gallin JI, Haraguchi S, Day NK, Casanova JL, Meffre E (2008) IRAK-4-and My D88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 29(5):746-757. doi:10.1016/j.immuni.2008.09.015
47. Herve M, Xu K, Ng YS, Wardemann H, Albesiano E, Messmer BT, Chiorazzi N, Meffre E (2005) Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 115(6):1636-1643. doi:10.1172/JCI24387 (Pubitemid 40814672)
48. Chen ZJ, Wheeler CJ, Shi W, Wu AJ, Yarboro CH, Gallagher M, Notkins AL (1998) Polyreactive antigen-binding B cells are the predominant cell type in the newborn B cell repertoire. Eur J Immunol 28(3):989-994. doi:10.1002/(SICI)1521- 4141(199803) 28:033.0.CO;2-1 (Pubitemid 28116212)
49. Chen ZJ, Wheeler J, Notkins AL (1995) Antigen-binding B cells and polyreactive antibodies. Eur J Immunol 25(2):579-586. doi: 10.1002/eji. 1830250241
50. Wang Z, Chen ZJ, Wheeler J, Shen S, Notkins AL (2001) Char-acterization of murine polyreactive antigen-binding B cells: presentation of antigens to T cells. Eur J Immunol 31(4):1106-1114. doi:10.1002/1521-4141(200104)31:43.0.CO;2- 5
51. Hayakawa K, Hardy RR, Parks DR, Herzenberg LA (1983) The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J Exp Med 157(1):202-218 (Pubitemid 13176184)
52. Burastero SE, Casali P (1989) Characterization of human CD5 (Leu-1, OKT1)+ B lymphocytes and the antibodies they pro-duce. Contrib Microbiol Immunol 11:231-262
53. Casali P, Notkins AL (1989) CD5+ B lymphocytes, polyreac-tive antibodies and the human B-cell repertoire. Immunol Today 10(11):364-368 (Pubitemid 19242061)
54. Martin F, Kearney JF (2000) Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk. Immunity 12(1):39-49. pii:S1074-7613(00)80157-0 (Pubitemid 30069213)
55. Li Y, Li H, Ni D, Weigert M (2002) Anti-DNA B cells in MRL/ lpr mice show altered differentiation and editing pattern. J Exp Med 196(12):1543-1552 (Pubitemid 36026466)
56. Zhou ZH, Notkins AL (2004) Polyreactive antigen-binding B (PAB-) cells are widely distributed and the PAB population consists ofboth B-1+ and B-1- phenotypes. Clin Exp Immunol 137(1):88-100. doi:10.1111/j.1365-2249.2004.02511.x (Pubitemid 38869782)
57. Sigounas G, Kolaitis N, Monell-Torrens E, Notkins AL (1994) Polyreactive Ig M antibodies in the circulation are masked by antigen binding. J Clin Immunol 14(6):375-381
58. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H, Zinkernagel RM (1999) Control ofearly viral and bacterial distribution and disease by natural antibodies. Science 286(5447):2156-2159. pii:8051 (Pubitemid 129516290)
59. Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA, Chen J (2000) B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med 192(2):271-280 (Pubitemid 30470309)
60. Zhou ZH, Zhang Y, Hu YF, Wahl LM, Cisar JO, Notkins AL (2007) The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 1(1):51-61. doi:10.1016/j.chom.2007.01.002 (Pubitemid 46506009)
61. Quan CP, Berneman A, Pires R, Avrameas S, Bouvet JP (1997) Natural polyreactive secretory immunoglobulin A autoantibod-ies as a possible barrier to infection in humans. Infect Immun 65(10):3997-4004 (Pubitemid 27422049)
62. Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J (1998) A critical role of natural immunoglobulin M in immediate defense againstsystemicbacterialinfection.JExp Med 188(12):2381-2386 (Pubitemid 29028511)
63. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H (2007) Autoreactivity in human Ig G+ memory B cells. Immunity26(2):205-213. doi:10.1016/j.immuni.2007.01.009 (Pubitemid 46329436)
64. Koelsch K, Zheng NY, Zhang Q, Duty A, Helms C, Mathias MD, Jared M, Smith K, Capra JD, Wilson PC (2007) Mature B cells class switched to Ig D are autoreactive in healthy individ-uals. J Clin Invest 117(6):1558-1565. doi:10.1172/JCI27628 (Pubitemid 46871340)
65. Quartier P, Bustamante J, Sanal O, Plebani A, Debre M, Deville A, Litzman J, Levy J, Fermand JP, Lane P, Horneff G, Aksu G, Yalcin I, Davies G, Tezcan I, Ersoy F, Catalan N, Imai K, Fischer A, Durandy A (2004) Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-Ig M syndrome due to activation-induced cytidine deaminase deficiency. Clin Immunol 110(1):22-29. doi:10.1016/j.clim.2003.10.007 (Pubitemid 38177417)
66. Shimoda M, Inoue Y, Azuma N, Kanno C (1999) Natural polyreactive immunoglobulin A antibodies produced in mouse Peyer's patches. Immunology 97(1):9-17. pii:imm755
67. Benckert J, Schmolka N, Kreschel C, Zoller MJ, Sturm A, Wiedenmann B, Wardemann H (2011) The majority of intestinal Ig A+ and Ig G+ plasmablasts in the human gut are antigen-specific. J Clin Invest 121(5):1946-1955. doi:10.1172/JCI44447
68. Kaetzel CS (2007) Mucosal immune defense: immunoglobulin A. Springer, New York
69. Mietzner B, Tsuiji M, Scheid J, Velinzon K, Tiller T, Abraham K, Gonzalez JB, Pascual V, Stichweh D, Wardemann H, Nus-senzweig MC (2008) Autoreactive Ig G memory antibodies in patients with systemic lupus erythematosus arise from nonre-active and polyreactive precursors. Proc Natl Acad Sci USA 105(28):9727-9732. doi:10.1073/pnas.0803644105 (Pubitemid 352031368)
70. Oppezzo P, Dumas G, Bouvet JP, Robello C, Cayota A, Pizarro JC, Dighiero G, Pritsch O (2004) Somatic mutations can lead to a loss of superantigenic and polyreactive binding. Eur J Immunol 34(5):1423-1432. doi:10.1002/eji.200424936 (Pubitemid 39256022)
71. Radic MZ, Mascelli MA, Erikson J, Shan H, Shlomchik M, Weigert M (1989) Structural patterns in anti-DNA antibodies from MRL/lpr mice. Cold Spring Harb Symp Quant Biol 54(Pt 2):933-946 (Pubitemid 20190215)
72. Radic MZ, Mackle J, Erikson J, Mol C, Anderson WF, Weigert M (1993) Residues that mediate DNA binding of autoimmune antibodies. J Immunol 150(11):4966-4977 (Pubitemid 23150364)
73. Wellmann U, Letz M, Herrmann M, Angermuller S, Kalden JR, Winkler TH (2005) The evolution of human anti-double-stran-ded DNA autoantibodies. Proc Natl Acad Sci USA 102(26): 9258-9263. doi:10.1073/pnas.0500132102 (Pubitemid 40923551)
74. Guo W, Smith D, Aviszus K, Detanico T, Heiser RA, Wysocki LJ (2010) Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity. J Exp Med 207(10):2225-2237. doi:10.1084/jem.20092712
75. Meffre E, Wardemann H (2008) B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 20(6):632-638. doi:10.1016/j.coi.2008.09.001
76. Wardemann H, Nussenzweig MC (2007) B-cell self-tolerance in humans. Adv Immunol 95:83-110. doi:10.1016/S0065-2776(07) 95003-8 (Pubitemid 47381589)
77. Zandman-Goddard G, Shoenfeld Y (2002) HIV and autoimmunity. Autoimmun Rev 1(6):329-337. pii:S1568997202000861 (Pubitemid 38340245)
78. Linder E, Kurki P, Andersson LC (1979) Autoantibody to "intermediate filament" in infectious mononucleosis. Clin Immunol Immunopathol 14(4):411-417 (Pubitemid 10161795)
79. Kataaha PK, Mortazavi-Milani SM, Russell G, Holborow EJ (1985) Anti-intermediate filament antibodies, antikeratin anti-body, and antiperinuclear factor in rheumatoid arthritis and infectious mononucleosis. Ann Rheum Dis 44(7):446-449 (Pubitemid 15071690)
80. Misra R, Venables PJ, Plater-Zyberk C, Watkins PF, Maini RN (1989) Anti-cardiolipin antibodies in infectious mononucleosis react with the membrane of activated lymphocytes. Clin Exp Immunol 75(1):35-40 (Pubitemid 19058771)
81. Mascia MT, Sandri G, Guerzoni C, Roncaglia R, Mantovani G, Ferri C (2008) Detection of autoimmunity in early primary Epstein-Barr virus infection by Western blot analysis. Clin Exp Rheumatol 26(6):1034-1039. pii:2520
82. Niller HH, Wolf H, Minarovits J (2008) Regulation and dys-regulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 41(4):298-328. doi:10.1080/08916930802024772 (Pubitemid 351593860)
83. Lidman K, Biberfeld G, Fagraeus A, Norberg R, Torstensson R, Utter G, Carlsson L, Luca J, Lindberg U (1976) Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 24(2):266-272
84. Kurki P, Virtanen I, Stenman S, Linder E (1978) Characteriza-tion of human smooth muscle autoantibodies reacting with cytoplasmic intermediate filaments. Clin Immunol Immunopa-thol 11(4):379-387 (Pubitemid 9075588)
85. Vento S, Mc Farlane BM, Mc Sorley CG, Ranieri S, Giuliani-Piccari G, Dal Monte PR, Verucchi G, Williams R, Chiodo F, Mc Farlane IG (1988) Liver autoreactivity in acute virus A, B and non-A, non-B hepatitis. J Clin Lab Immunol 25(1):1-7 (Pubitemid 18073697)
86. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Fran-cesconi R, Muratori L, Lenzi M, Bianchi G, Zauli D, Bianchi FB (1997) Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 26(3):561-566. doi:10.1002/hep. 510260305 (Pubitemid 27392344)
87. Toh BH, Yildiz A, Sotelo J, Osung O, Holborow EJ, Kanakoudi F, Small JV (1979) Viral infections and Ig M autoantibodies to cyto-plasmic intermediate filaments. Clin Exp Immunol 37(1):76-82 (Pubitemid 9201948)
88. Dales S, Fujinami RS, Oldstone MB (1983) Infection with vaccinia favors the selection of hybridomas synthesizing auto-antibodies against intermediate filaments, one of them cross-reacting with the virus hemagglutinin. J Immunol 131(3): 1546-1553 (Pubitemid 13048921)
89. Hunziker L, Recher M, Macpherson AJ, Ciurea A, Freigang S, Hengartner H, Zinkernagel RM (2003) Hypergammaglobuline-mia and autoantibody induction mechanisms in viral infections. Nat Immunol 4(4):343-349. doi:10.1038/ni911 (Pubitemid 36432316)
90. Ludewig B, Krebs P, Metters H, Tatzel J, Tureci O, Sahin U (2004) Molecular characterization of virus-induced autoanti-body responses. J Exp Med 200(5):637-646. doi:10.1084/jem. 20040358 (Pubitemid 38252049)
91. Munz C, Lunemann JD, Getts MT, Miller SD (2009) Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 9(4):246-258. doi:10.1038/nri2527
92. Fujinami RS, Oldstone MB, Wroblewska Z, Frankel ME, Koprowski H (1983) Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci USA 80(8):2346-2350 (Pubitemid 13097186)
93. Coutelier JP, Coulie PG, Wauters P, Heremans H, van der Logt JT (1990) In vivo polyclonal B-lymphocyte activation elicited by murine viruses. J Virol 64(11):5383-5388 (Pubitemid 20364529)
94. Lunemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, Munz C (2008) EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 205(8):1763-1773. doi:10.1084/jem.20072397
95. Lunemann JD, Munz C (2009) EBV in MS: guilty by association? Trends Immunol 30(6):243-248. doi:10.1016/j.it.2009.03.007
96. Hoxie JA, Fitzharris TP, Youngbar PR, Matthews DM, Rac-kowski JL, Radka SF (1987) Nonrandom association of cellular antigens with HTLV-III virions. Hum Immunol 18(1):39-52. pii:0198-8859(87)90111-X (Pubitemid 17221876)
97. Kopelman RG, Zolla-Pazner S (1988) Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med 84(1):82-88. pii:0002-9343(88)90012-5
98. Solinger AM, Adams LE, Friedman-Kien AE, Hess EV (1988) Acquired immune deficiency syndrome (AIDS) and autoimmu-nity-mutually exclusive entities? J Clin Immunol 8(1):32-42 (Pubitemid 18066780)
99. Ditzel HJ, Itoh K, Burton DR (1996) Determinants of polyre-activity in a large panel of recombinant human antibodies from HIV-1 infection. J Immunol 157(2):739-749 (Pubitemid 26231378)
100. Harkiss GD, Veitch D, Dickson L, Watt NJ (1993) Autoimmune reactivity in sheep induced by the visna retrovirus. J Autoimmun 6(1):63-75. doi:10.1006/jaut.1993.1006 (Pubitemid 23061333)
101. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393(6686):705-711. doi:10.1038/31514 (Pubitemid 28289663)
102. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM (2005) Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 14(3-4):59-67
103. Alam SM, Mc Adams M, Boren D, Rak M, Scearce RM, Gao F, Camacho ZT, Gewirth D, Kelsoe G, Chen P, Haynes BF (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 mem-brane proximal envelope epitopes. J Immunol 178(7):4424-4435. pii:178/7/4424
104. Matyas GR, Beck Z, Karasavvas N, Alving CR (2009) Lipid binding properties of 4E10, 2F5, and WR304 monoclonal anti-bodies that neutralize HIV-1. Biochim Biophys Acta 1788(3):660-665. doi:10.1016/j.bbamem.2008.11.015
105. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC (2009) Broad diversity of neutralizing anti-bodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238):636-640. doi:10.1038/nature07930
106. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Cha-kraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467(7315):591-595. doi:10.1038/nature09385
107. Dennison SM, Anasti K, Scearce RM, Sutherland L, Parks R, Xia SM, Liao HX, Gorny MK, Zolla-Pazner S, Haynes BF, Alam SM (2011) Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. J Virol 85(3):1340-1347. doi:10.1128/JVI.01680-10
108. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, Chen B, Parks R, Foulger A, Jaeger F, Donathan M, Bilska M, Gray ES, Abdool Karim SS, Kepler TB, Whitesides J, Monte-fiori D, Moody MA, Liao HX, Haynes BF (2011) Isolation of a Human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLo S One 6 (9):e23532. doi:10.1371/journal.pone.0023532
109. Liao HX, Chen X, Munshaw S, Zhang R, Marshall DJ, Van-dergrift N, Whitesides JF, Lu X, Yu JS, Hwang KK, Gao F, Markowitz M, Heath SL, Bar KJ, Goepfert PA, Montefiori DC, Shaw GC, Alam SM, Margolis DM, Denny TN, Boyd SD, Marshal E, Egholm M, Simen BB, Hanczaruk B, Fire AZ, Voss G, Kelsoe G, Tomaras GD, Moody MA, Kepler TB, Haynes BF (2011) Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med. doi:10.1084/jem.20110363
110. Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, Velinzon K, Seaman MS, Nussenzweig MC (2011) Mem-ory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLo S One 6 (9):e24078. doi:10.1371/journal.pone.0024078
111. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oli-vera TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton D, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. doi: 10.1126/science.1207227
112. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, Mc Kee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329(5993):856-861. doi:10.1126/science.1187659
113. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329(5993):811-817. doi:10.1126/ science.1192819
114. Ishigatsubo Y, Steinberg AD, Krieg A, Klinman DM (1995) Increased utilization of polyreactive B cells during periods of generalized immune activation. Autoimmunity 22(2):113-119 (Pubitemid 26138758)
115. Llorente M, Sanchez-Palomino S, Manes S, Lucas P, Kremer L, De Alboran IM, Toran JL, Alcami J, Del Real G, Martinez AC (1999) Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes. Scand J Immunol 50(3):270-279. pii:sji516
116. Karle S, Planque S, Nishiyama Y, Taguchi H, Zhou YX, Salas M, Lake D, Thiagarajan P, Arnett F, Hanson CV, Paul S (2004) Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS 18(2):329-331. pii:0000 2030-200401230-00026 (Pubitemid 38253459)
117. Mancini N, Perotti M, Carletti S, Canducci F, Sampaolo M, Clementi M, Burioni R (2006) Cloning and molecular charac-terization of a human recombinant Ig G Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient. Mol Immunol 43(9):1363-1369. doi:10.1016/j.molimm.2005.08. 003 (Pubitemid 43361593)
118. Scherl M, Posch U, Obermoser G, Ammann C, Sepp N, Ulmer H, Dierich MP, Stoiber H, Falkensammer B (2006) Targeting human immunodeficiency virus type 1 with antibodies derived from patients with connective tissue disease. Lupus 15(12):865-872 (Pubitemid 46049691)
119. Russo S, Lopalco L (2006) Is autoimmunity a component of natural immunity to HIV? Curr HIV Res 4(2):177-190
120. Levy JA (2007) HIV and the pathogenesis of AIDS, 3rd edn. ASM, Blackwell [distributor], Washington, Oxford
121. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM (2003) Antibody neutralization and escape by HIV-1. Nature 422(6929):307-312. doi:10.1038/nature01470 (Pubitemid 36378357)
122. Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, Schief WR, Sanders RW (2010) Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 84(11):5637-5655. doi: 10.1128/JVI.00105-10
123. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Maj-eed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420(6916):678-682. doi:10.1038/nature01188 (Pubitemid 36764500)
124. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR (2003) Access of antibody molecules to the conserved coreceptor binding site on glyco-protein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77(19):10557-10565 (Pubitemid 37129699)
125. Schief WR, Ban YE, Stamatatos L (2009) Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 4(5):431-440. doi:10.1097/COH. 0b013e32832e6184
126. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B (2008) A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA 105(10):3739-3744. doi:10.1073/pnas. 0800255105 (Pubitemid 351723468)
127. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441(7095):847-852. doi:10.1038/nature04817
128. Klein JS, Bjorkman PJ (2010) Few and far between: how HIV may be evading antibody avidity. PLo S Pathog 6 (5):e1000908. doi:10.1371/journal.ppat.1000908
129. Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP Jr, Bjorkman PJ (2009) Examination of the contribu-tions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci USA 106(18):7385-7390. doi:10.1073/pnas.0811427106
130. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, Kwong PD (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78(19):10724-10737. doi:10.1128/JVI.78.19.10724-10737.2004 (Pubitemid 39258398)
131. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22(2):163-173. doi:10.1016/j.immuni.2004.12.011 (Pubitemid 40255708)
132. Sanchez-Martinez S, Lorizate M, Katinger H, Kunert R, Nieva JL (2006) Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 22(10):998-1006. doi:10.1089/aid.2006.22.998 (Pubitemid 46100685)
133. Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, Song L, Qiao Z, Wang JH, Wagner G, Reinherz EL (2008) HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28(1):52-63. doi: 10.1016/j.immuni.2007.11.018
134. Huarte N, Lorizate M, Kunert R, Nieva JL (2008) Lipid mod-ulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies. FEBS Lett 582(27):3798-3804. doi:10.1016/j.febslet.2008.10.012
135. Huarte N, Lorizate M, Maeso R, Kunert R, Arranz R, Valpuesta JM, Nieva JL (2008) The broadly neutralizing anti-human immunode-ficiency virus type 14E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5. J Virol 82(18):8986-8996. doi:10.1128/JVI.00846-08
136. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, Xia SM, Rits-Volloch S, Sun L, Harrison SC, Haynes BF, Chen B (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 106(48): 20234-20239. doi:10.1073/pnas.0908713106
137. Brown BK, Karasavvas N, Beck Z, Matyas GR, Birx DL, Pol-onis VR, Alving CR (2007) Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodefi-ciency virus type 1: role ofphosphate-binding subsites. J Virol 81(4):2087-2091. doi:10.1128/JVI.02011-06 (Pubitemid 46214483)
138. Veiga AS, Pattenden LK, Fletcher JM, Castanho MA, Aguilar MI (2009) Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems. Chem biochem 10(6):1032-1044. doi:10.1002/cbic.200800609
139. Scherer EM, Leaman DP, Zwick MB, Mc Michael AJ, Burton DR (2010) Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci USA 107(4):1529-1534. doi:10.1073/pnas.0909680107
140. Diskin R, Marcovecchio PM, Bjorkman PJ (2010) Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol 17(5):608-613. doi:10.1038/nsmb.1796
141. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, Mc Bride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA (2011) A Potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. doi:10.1126/science.1213256
142. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Principal Investi-gators PG, Koff WC, Wilson IA, Burton DR, Poignard P (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477(7365):466-470. doi: 10.1038/nature10373
143. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950):285-289. doi: 10.1126/science.1178746
144. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, White-sides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neu-tralizing antibodies and their inferred unmutated common ancestors. J Virol 85(19):9998-10009. doi:10.1128/JVI. 05045-11
145. Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM, Liao HX, Kelsoe G, Haynes BF (2010) Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 107(1):181-186. doi:10.1073/pnas.0912914107
146. Verkoczy L, Chen Y, Bouton-Verville H, Zhang J, Diaz M, Hutchinson J, Ouyang YB, Alam SM, Holl TM, Hwang KK, Kelsoe G, Haynes BF (2011) Rescue of HIV-1 broad neutral-izing antibody-expressing B cells in 2F5 VH x VL Knockin mice reveals multiple tolerance controls. J Immunol 187(7):3785-3797. doi:10.4049/jimmunol.1101633
147. Scherer EM, Zwick MB, Teyton L, Burton DR (2007) Diffi-culties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21(16):2131-2139. doi:10.1097/QAD. 0b013e3282a4a632 (Pubitemid 350287210)
148. Singh H, Henry KA, Wu SS, Chruscinski A, Utz PJ, Scott JK (2011) Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies. AIDS 25(10):1247-1257. doi:10.1097/QAD.0b013e32834785cf
149. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453(7195):667-671. doi:10.1038/nature06890 (Pubitemid 351769295)
150. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, Mc Causland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208(1):181-193. doi:10.1084/jem.20101352
151. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328(5979): 745-748. doi: 10.1126/science.1185181
152. Beltramello M, Williams KL, Simmons CP, Macagno A, Si-monelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8(3):271-283. doi: 10.1016/j.chom.2010.08.007
153. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A (2010) Iso-lation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the g H/g L/UL128-131A complex. J Virol 84(2):1005-1013. doi:10.1128/JVI.01809-09
154. Scheid JF, Mouquet H, Kofer J, Yurasov S, Nussenzweig MC, Wardemann H (2011) Differential regulation of self-reactivity discriminates between Ig G+ human circulating memory B cells and bone marrow plasma cells. Proc Natl Acad Sci USA. doi: 10.1073/pnas.1113395108